Identifying metabolic markers for preventing atrial fibrillation
Identification of the Metabolic Signature of Atrial Fibrillation for Personalized Prevention
This study is trying to find specific metabolic markers in patients having heart surgery to see if they can help predict and prevent the return of atrial fibrillation.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 400 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Bordeaux Academic / other |
| Locations | 1 site (Pessac) |
| Trial ID | NCT06735001 on ClinicalTrials.gov |
What this trial studies
This study aims to identify metabolic and biomolecular signatures associated with atrial fibrillation (AF) in patients scheduled for cardiac ablation. By monitoring these signatures over a 12-month period, the research seeks to develop a method for assessing the risk of AF recurrence. The approach combines traditional risk factors with metabolic biomarkers using machine learning techniques to enhance personalized prevention strategies. The ultimate goal is to improve outcomes for patients at risk of AF by providing tailored interventions.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older who are scheduled for cardiac ablation due to atrial fibrillation.
Not a fit: Patients under 18, those with active tumors, or individuals with certain chronic diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to personalized prevention strategies that significantly reduce the recurrence and progression of atrial fibrillation.
How similar studies have performed: While the approach of identifying metabolic signatures is innovative, similar studies have shown promise in other cardiovascular conditions, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years, all genders, and ethnic origins * Free, informed, and written consent signed * Person affiliated to or benefiting from a social security scheme Exclusion Criteria: * Age \< 18 years * Lack of informed consent * Gestating women (pregnancy test carried out as part of care for FA patients, contraception, or menopause for women in control groups) * Persons under administrative or judicial protection * Endocarditis or pericarditis in progress or within the 3 last months * Active tumor pathology (benign or malignant) * Chronic inflammation or autoimmune disease * Chronic liver disease * Myocardial infarction within the last 8 weeks
Where this trial is running
Pessac
- University Hospital of Bordeaux — Pessac, France (Recruiting)
Study contacts
- Principal investigator: Nicolas DERVAL — University Hospital, Bordeaux
- Study coordinator: Guido CALUORI
- Email: guido.caluori@ihu-liryc.fr
- Phone: +33 5 35 38 19 58
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.